“Repeat dose toxicology studies were conducted with elacestrant in rats and monkeys for up to 26 and 39 weeks, respectively, administered via daily oral gavage”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Why that species
Monkey chosen as non-rodent because its reproductive system morphology, hormonal changes and menstrual cycle closely resemble humans
“The Applicant provided a justification for the use of non-human primates as non-rodent species, indicating that morphological and hormonal changes in the reproductive system and menstrual cycle phases of monkeys closely resemble those of humans.”
“Repeat dose toxicology studies were conducted with elacestrant in rats and monkeys for up to 26 and 39 weeks, respectively, administered via daily oral gavage”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Species: general tox
Rat (26-week) and cynomolgus monkey (39-week)
“Repeat dose toxicology studies were conducted with elacestrant in rats and monkeys for up to 26 and 39 weeks, respectively, administered via daily oral gavage”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Species: DART
Rat (EFD only); fertility and pre/postnatal studies not conducted per ICH S9
“The Applicant assessed the effects of elacestrant on reproductive organs in the rat and monkey as part of the GLP-compliant repeat-dose toxicology studies and provided results from a GLP-compliant embryofetal development (EFD) study in rats.”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Species: carcinogenicity
Not conducted (ICH S9)
“Carcinogenicity studies were not conducted with elacestrant in accordance with ICH S9 guidance”
✓ VerifiedFDA multi-discipline review, p. 42Source ↗
Surrogate used in
No surrogate used; elacestrant tested directly
“Repeat dose toxicology studies were conducted with elacestrant in rats and monkeys for up to 26 and 39 weeks, respectively, administered via daily oral gavage”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗